Helix BioPharma (TSE:HBP) Reaches New 12-Month High - Here's Why

Key Points

• Helix BioPharma's stock price reached a new 52-week high of C$1.37, compared to its previous close of C$1.29, with a trading volume of 5,724 shares.
• The company has a market cap of C$72.64 million and is primarily focused on developing cancer therapies through its proprietary immuno-oncology technology.
• Helix BioPharma currently has a P/E ratio of -1.44 and significant improvements in its moving averages, with 50-day at C$1.00 and 200-day at C$0.92.

Helix BioPharma Corp. (TSE:HBP - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$1.37 and last traded at C$1.37, with a volume of 5724 shares. The stock had previously closed at C$1.29.

Helix BioPharma Stock Performance

The stock has a fifty day moving average price of C$1.04 and a 200-day moving average price of C$0.94. The firm has a market cap of C$71.58 million, a PE ratio of -1.42 and a beta of -0.84.

About Helix BioPharma

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.